Research Grade Rosmantuzumab (DHJ51101)

Catalog No.

DHJ51101

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

RSPO3, hPWTSR, hRspo3, PWTSR, R-spondin-3, Thrombospondin type-1 domain-containing protein 2, Protein with TSP type-1 repeat, Roof plate-specific spondin-3, THSD2

Concentration

1.72 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q9BXY4

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

OMP-131R10, CAS: 1684393-04-1

Clone ID

Rosmantuzumab

Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review), PMID: 29786110

Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review), PMID: 29048660

Molecular genetics and targeted therapy of WNT-related human diseases (Review), PMID: 28731148

Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia, PMID: 32559496

Targeted activation of ferroptosis in colorectal cancer via LGR4 targeting overcomes acquired drug resistance. [DHJ51101]

Document Download

Research Grade Rosmantuzumab.pdf